PT  - JOURNAL ARTICLE
AU  - Choon-Myung Lee
AU  - Vikas Kumar
AU  - Rochelle I. Riley
AU  - Edward T. Morgan
TI  - Metabolism and Action of Proteasome Inhibitors in Primary Human Hepatocytes
AID  - 10.1124/dmd.110.035501
DP  - 2010 Dec 01
TA  - Drug Metabolism and Disposition
PG  - 2166--2172
VI  - 38
IP  - 12
4099  - http://dmd.aspetjournals.org/content/38/12/2166.short
4100  - http://dmd.aspetjournals.org/content/38/12/2166.full
SO  - Drug Metab Dispos2010 Dec 01; 38
AB  - Proteasome inhibitors are important tools for studying the roles of the proteasome in cellular processes. In this study, we observed that the proteasome inhibitors N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132), epoxomicin, and lactacystin were ineffective and bortezomib was completely effective in inhibiting cytokine-stimulated nitric oxide production in primary cultures of human hepatocytes that had been treated with the cytochrome P450 inducer phenobarbital. The inefficacy of MG132 was due to its metabolism by CYP3A enzymes, as deduced from its rapid, ketoconazole-sensitive clearance by pooled human liver microsomes and cultured hepatocytes. The efficacy of MG132 was increased by inclusion of ketoconazole in the hepatocyte incubations and decreased by prior treatment of the cultures with the CYP3A inducers phenobarbital or rifampicin. Epoxomicin was also rapidly metabolized by CYP3A, whereas bortezomib and lactacystin were much more stable metabolically in human liver microsomes or hepatocyte cultures. Thus, bortezomib is a better choice than MG132, epoxomicin, or lactacystin in cells with high activities of CYP3A enzymes. The reason for the lack of efficacy of lactacystin in human hepatocytes has yet to be determined, but it too should not be used for studies of proteasome function in human hepatocytes.